We add to the existing literature the fact that novel CSF p‐tau biomarkers (N‐p‐tau181, N‐p‐tau217 or Mid‐p‐tau231) are closely linked to Aβ pathology in sporadic AD, even when this Aβ pathology is very subtle. This evidence concerns the gene MAPT and Alzheimer disease.